Neogene Therapeutics is now a part of the AstraZeneca Group. Visit AstraZeneca.com AstraZeneca.com

Introduction Adoptive transfer of T cell receptor (TCR) edited T cells to target cancer neoantigens is a promising new immunotherapy approach. Neogene Therapeutics is developing both patient-specific and shared neoantigen TCR programs to introduce such TCRs into a patient’s own T cells, redirecting their antigen specificity.

Dr. Gavin M. Bendle is the Senior Vice President of Research and Development at Neogene Therapeutics. He has been actively engaged in the field of adoptive T cell therapy of cancer for over 17 years and has co-authored numerous publications on this subject. Before joining Neogene, Dr. Bendle was a Senior Director of Cell Therapy […]

Sign in with Neogene Sign in with AstraZenecaNeogene T-Cell Processing

The post Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumorsappeared first on Neogene Therapeutics.

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

US Headquarters Neogene Therapeutics, Inc. 2225 Colorado Ave Santa Monica, CA 90404 United States